Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab Tesirine QT/QTc Study in SCLC
NCT02874664Phase 1Completed
- Sponsor
- Stemcentrx
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by Stemcentrx. Primary endpoint: Change in QTcF interval from baseline at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02874664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874664.